[1] Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl,2017,23(11):1451-1464.
[2] Meza-Junco J, Montano-Loza AJ, Baracos VE, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol, 2013,47(10):861-870.
[3] Ando Y, Ishigami M, Ito T, et al. Sarcopenia impairs health-related quality of life in cirrhotic patients. Eur J Gastroenterol Hepatol, 2019,31(12):1550-1556.
[4] Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol,2012,10(2):166-173.
[5] Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology, 2021,74(3):1611-1644.
[6] Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition,2001,17(6):445-450.
[7] Plauth M, Cabré E, Campillo B, et al. ESPEN Guidelines on Parenteral Nutrition: hepatology. Clin Nutr,2009,28(4):436-444.
[8] Chen CJ, Wang LC, Kuo HT, et al. Significant effects of late evening snack on liver functions in patients with liver cirrhosis: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol, 2019,34(7):1143-1152.
[9] Duarte-Rojo A, Ruiz-Margáin A, Montaño-Loza AJ, et al. Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl,2018,24(1):122-139.
[10] Jones JC, Coombes JS, Macdonald GA. Exercise capacity and muscle strength in patients with cirrhosis. Liver Transpl,2012,18(2):146-151.
[11] García-Pagàn JC, Santos C, Barberá JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology,1996,111(5):1300-1306.
[12] Macías-Rodríguez RU, Ilarraza-Lomelí H, Ruiz-Margáin A, et al. Changes in hepatic venous pressure gradient induced by physical exercise in cirrhosis: Results of a pilot randomized open clinical trial. Clin Transl Gastroenterol,2016,7(7):e180.
[13] European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol,2019,70(1):172-193.
[14] Tandon P, Ismond KP, Riess K, et al. Exercise in cirrhosis: Translating evidence and experience to practice. J Hepatol,2018,69(5):1164-1177.
[15] Bunchorntavakul C, Reddy KR. Malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther,2020,51(1):64-77.
[16] Córdoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol,2004,41(1):38-43.
[17] Teratani T, Tomita K, Suzuki T, et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology, 2012,142(1):152-164.
[18] Keohane PP, Attrill H, Grimble G, et al. Enteral nutrition in malnourished patients with hepatic cirrhosis and acute encephalopathy. JPEN J Parenter Enteral Nutr, 1983,7(4):346-350.
[19] Weimann A, Braga M, Carli F, et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr, 2017,36(3):623-650.
[20] Reintam Blaser A, Starkopf J, Alhazzani W, et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med, 2017,43(3):380-398.
[21] Verlaan S, Aspray TJ, Bauer JM, et al. Nutritional status, body composition, and quality of life in community-dwelling sarcopenic and non-sarcopenic older adults: A case-control study. Clin Nutr, 2017,36(1):267-274.
[22] Rossi RE, Conte D, Massironi S. Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues. Dig Liver Dis,2015,47(10):819-825.
[23] Katayama K. Zinc and protein metabolism in chronic liver diseases. Nutr Res,2020,74:1-9.
[24] Ding N, Yu RT, Subramaniam N, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell, 2013,153(3):601-613.
[25] Uchitomi R, Oyabu M, Kamei Y. Vitamin D and sarcopenia: Potential of vitamin D supplementation in sarcopenia prevention and treatment. Nutrients, 2020,12(10):3189.
[26] Beaudart C, Buckinx F, Rabenda V, et al. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab,2014,99(11):4336-4345.
[27] Tomlinson PB, Joseph C, Angioi M. Effects of vitamin D supplementation on upper and lower body muscle strength levels in healthy individuals. A systematic review with meta-analysis. J Sci Med Sport, 2015,18(5):575-580.
[28] Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev, 2017,5(5):CD001939.
[29] Konstantis G, Pourzitaki C, Chourdakis M, et al. Efficacy of branched chain amino acids supplementation in liver cirrhosis: A systematic review and meta-analysis. Clin Nutr, 2022,41(6):1171-1190.
[30] Kawaguchi T, Shiraishi K, Ito T, et al. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol, 2014,12(6):1012-1018,e1.
[31] Nissen S, Sharp R, Ray M, et al. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol (1985), 1996,81(5):2095-2104.
[32] Hole ek M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions. J Cachexia Sarcopenia Muscle,2017,8(4):529-541.
[33] Espina S, Sanz-Paris A, Gonzalez-Irazabal Y, et al. Randomized clinical trial: Effects of β-hydroxy-β-methylbutyrate (HMB)-enriched vs. HMB-free oral nutritional supplementation in malnourished cirrhotic patients.Nutrients,2022,14(11):2344.
[34] Lattanzi B, Bruni A, Di Cola S, et al. The effects of 12-week beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: Results from a randomized controlled single-blind pilot study. Nutrients, 2021,13(7):2296.
[35] Dalle S, Rossmeislova L, Koppo K. The role of inflammation in age-related sarcopenia. Front Physiol,2017;8:1045.
[36] Ochi E, Tsuchiya Y. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in muscle damage and function. Nutrients, 2018,10(5):552.
[37] Tan A, Sullenbarger B, Prakash R, et al. Supplementation with eicosapentaenoic acid and docosahexaenoic acid reduces high levels of circulating proinflammatory cytokines in aging adults: A randomized, controlled study. Prostaglandins Leukot Essent Fatty Acids, 2018,132:23-29.
[38] Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr, 2011,93(2):402-412.
[39] Zacharias BT, Coelho JC, Parolin MB, et al. Hypothalamic-pituitary-gonadal function in men with liver cirrhosis before and after liver transplantation. Rev Col Bras Cir, 2014,41(6):421-425.
[40] Sinclair M, Grossmann M, Gow PJ, et al. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol, 2015,30(2):244-251.
[41] Moctezuma-Velázquez C, Low G, Mourtzakis M, et al. Association between Low Testosterone Levels and Sarcopenia in Cirrhosis: A Cross-sectional Study. Ann Hepatol, 2018,17(4):615-623.
[42] Sinclair M, Gow PJ, Grossmann M,et al. Angus PW. Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score. Liver Transpl, 2016,22(11):1482-1490.
[43] Paternostro R, Heinisch BB, Reiberger T, et al. Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. Hepatol Res, 2019,49(2):201-211.
[44] Puliyel MM, Vyas GP, Mehta GS. Testosterone in the management of cirrhosis of the liver-a controlled study. Aust N Z J Med, 1977,7(6):17-30.
[45] Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J Hepatol, 2016,65(5):906-8913.
[46] Grech A, Breck J, Heidelbaugh J. Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. Ther Adv Drug Saf, 2014,5(5):190-200.
[47] Maheshwari A, Thuluvath PJ. Endocrine diseases and the liver. Clin Liver Dis,2011,15(1):55-67.
[48] Gluud C, Dejgaard A, Bennett P, et al. Androgens and oestrogens before and following oral testosterone administration in male patients with and without alcoholic cirrhosis. Acta Endocrinol, 1987,115(3):385-391.
[49] Karlic H, Lohninger A. Supplementation of L-carnitine in athletes: does it make sense? Nutrition, 2004,20(7-8):709-715.
[50] Rudman D, Sewell CW, Ansley JD. Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest, 1977,60(3):716-723.
[51] Hiramatsu A, Aikata H, Uchikawa S, et al. Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. Hepatol Commun, 2019,3(3):348-355.
[52] Koeth RA, Lam-Galvez BR, Kirsop J, et al. l-carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest, 2019,129(1):373-387.
[53] Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol, 2021,56(7):593-619. |
